SignalMacro

DRUG DEVELOPER ADARX SEEKS $1.74 BILLION VALUATION IN US IPO - YAHOO

Drug developer Adarx targets $1.74 billion valuation in US IPO.

What changed

Drug developer Adarx targets $1.74 billion valuation in US IPO.

Why it matters

Drug developer Adarx targets $1.74 billion valuation in US IPO. — impact context not separately stored; see What changed.

Sources